Atopic Dermatitis

The study found that 59% of patients achieved IGA treatment success, surpassing other topical therapies.

Cases of dermatitis in workers and consumers alike show how allergen exposure transcends occupational boundaries.

Renata Block, DMSc, MMS, PA-C, and Isabelle Thibau, MPH, of the National Eczema Association discuss how the EczemaWise app integrates patient-reported outcomes, validated tools, and real-world data to improve collaboration between patients and clinicians in managing eczema.

Case reports showed encouraging outcomes in eczema, but the company is pursuing deeper validation.

Clinicians explore innovative strategies for managing atopic dermatitis, emphasizing personalized care and the use of non-steroidal treatments for improved patient outcomes.

April Martinez-Dulay, MSN, APRN, FNP-BC, shares insights on diagnosing and treating types of dermatitis at DERM 2025, emphasizing innovative approaches and patient care strategies.

Walter Liszewski, MD, shares expert strategies for managing body surface area limitations in AD treatment using non-steroidal topicals, and explored key unmet needs in the current therapeutic landscape.

James Song, MD, FAAD, reveals insights on abrocitinib's safety in atopic dermatitis, highlighting lower conjunctivitis rates compared to dupilumab at DERM 2025.

At the Elevate-Derm Summer 2025 meeting, Walter Liszewksi, MD, discussed how new topical therapies, particularly JAK inhibitors, are transforming AD care with rapid itch relief, effectiveness in complex cases, and patient-friendly formulations for sensitive areas.

Explore expert insights from Adam Friedman, MD, FAAD, on emerging topical treatments for atopic dermatitis, featuring real-world cases and practical strategies for improving care and access.

Expanded prescribing rights for pharmacists could ease treatment delays and improve access for AD patients.

Walter Liszewski, MD, discusses the personalized and evolving treatment landscape for moderate to severe AD, emphasizing a tailored approach using new biologics and non-steroidal topicals to meet individual patient needs and expectations.

Discover how the NEA Seal of Acceptance helps clinicians recommend safe eczema products, ensuring quality and sensitivity for patients with atopic dermatitis.

Explore innovative nonsteroidal treatments for atopic dermatitis, as experts discuss personalized care strategies to enhance patient quality of life.

Explore personalized systemic therapies for atopic dermatitis, addressing patient needs, treatment options, and enhancing adherence for better outcomes.

Tina Bhutani, MD, MAS, highlights emerging topical treatments for pediatric atopic dermatitis, emphasizing improved adherence in younger children, the potential impact of ruxolitinib FDA approval for ages 2 and up, and the promise of ongoing trials in infants under 2 years.

Robert Koppel, MD, led Case-Based Roundtable attendees through 3 complex cases of atopic dermatitis that centered around available non-steroidal topicals and biologics.

Tina Bhutani, MD, MAS, discusses innovative pediatric atopic dermatitis treatments, including ruxolitinib cream, emphasizing collaborative decision-making for effective management.

Shanna Miranti, MPAS, PA-C, discusses the impact of sleep loss in pediatric atopic dermatitis and the potential of emerging therapies in young patients, such as ruxolitinib cream, to improve outcomes.

Temitayo Ogunleye, MD, guided clinicians through diverse AD cases to examine how newer agents fit into evolving treatment strategies.

Cutaneous immune-related adverse events (cirAEs) from immune checkpoint inhibitors (ICIs) show distinct immune profiles from classic skin conditions.

Amlitelimab shows promise in enhancing clinical outcomes and patient quality of life in atopic dermatitis, offering potential for long-term disease control.

The Japanese study found no association between cutaneous events and baseline EASI scores, eosinophil counts, or IgE levels.

In a discussion on pediatric AD management, Shanna Miranti, MPAS, PA-C, emphasized the enduring role of topical treatments for residual itch and flares, and highlighted the importance of rapid-acting agents such as ruxolitinib cream.

At a recent Dermatology Times Case-Based Roundtable, attendees discussed several challenging AD cases.